IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.7% in the fourth quarter, HoldingsChannel reports. The firm owned 1,689 shares of the company’s stock after selling 161 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in IDEXX Laboratories were worth $937,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IDXX. Gotham Asset Management LLC boosted its stake in shares of IDEXX Laboratories by 79.9% in the 3rd quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after buying an additional 7,741 shares during the period. NewEdge Wealth LLC increased its stake in shares of IDEXX Laboratories by 30.4% during the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock worth $279,000 after buying an additional 149 shares during the period. Assenagon Asset Management S.A. raised its holdings in IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock valued at $24,196,000 after acquiring an additional 8,831 shares in the last quarter. Carderock Capital Management Inc. lifted its stake in IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after acquiring an additional 4,315 shares during the last quarter. Finally, Mitchell Capital Management Co. grew its holdings in IDEXX Laboratories by 1.3% during the 3rd quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock worth $2,786,000 after acquiring an additional 79 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares in the company, valued at $45,377,624.67. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 1.0 %

Shares of NASDAQ IDXX opened at $480.60 on Friday. The business has a 50-day moving average price of $525.21 and a 200 day moving average price of $512.07. The stock has a market cap of $39.69 billion, a PE ratio of 46.52, a price-to-earnings-growth ratio of 3.74 and a beta of 1.27. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same period last year, the firm earned $2.05 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.06 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Barclays cut their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. The Goldman Sachs Group raised their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $580.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.